-EARNINGS RELEASE-

ELRON ELECTRONIC INDUSTRIES ANNOUNCES SECOND QUARTER 2006 RESULTS

Tel Aviv, Israel, August 14, 2006 - Elron Electronic Industries Ltd. (NASDAQ:ELRN) today reported a net loss for the second quarter and for the first half of 2006 of \$6.4 million, or \$0.22 per share, and \$9.9 million, or \$0.34 per share, respectively. In the first quarter and first half of 2005, Elron reported net income of \$47.2 million, or \$1.60 per share, and \$42.1 million, or \$1.43 per share, respectively.

Elron's net loss in the second quarter and the first half of 2006 resulted from Elron's share in the net losses of its group companies, amounting to \$7.0 million and \$12.0 million, respectively, and from the absence of gains from sales of shares of group companies in both periods.

The net income Elron reported in the second quarter and first half of 2005 was mainly due to gains resulting from sale of shares of group companies, which were partially offset by losses, net, which Elron recorded with respect to its group companies in the amount of \$7.4 million and \$12.2 million in the second quarter and first half of 2005, respectively.

Liquidity and Shareholders Equity

As of June 30, 2006, Elron's cash, debentures and deposits amounted to approximately \$113.8 million compared with \$133.8 million at December 31, 2005. During the first half of 2006, Elron invested approximately \$21.1 million in new and existing group companies.

Shareholders' equity at June 30, 2006, was approximately \$291.4 million, representing approximately 87% of the total assets compared with \$302.1 million representing approximately 85% of the total assets at December 31, 2005.

"During the second quarter, we continued to invest in and build our group companies. NetVision's advanced negotiations to acquire Barak and Globecall, Wavion's product launch and the completion of a \$14 million private placement in AMT, are examples of recent developments which will result in future value to shareholders" said Doron Birger, Elron's President and CEO. "In addition, our strong cash position enables us to continue investing in our group companies as well as in new opportunities".

Mr. Birger added, "We and our group companies have operated continuously throughout the recent events which have affected the north of Israel. Currently, the impact on us and our group companies, if any, has not been significant."

Investors may access Elron's second quarter financial report and a detailed management report on the company's web site: www.elron.com

Conference call details:

Monday, August 14, 2006 10:00 a.m. (EST); 17:00 p.m. Israel Dial in numbers:

In the US: 1-866 229 7198

In the UK: 0 800 917 5108

In Israel: 03 918 0600

International Participants: +972 3 918 2700

For your convenience, a **replay of the call** will be available starting two hours after the call ends until Wednesday, August 16, 2006. To access the replay please dial **1-866-276-1485(US)**, **972-3-925-5942 (Israel) and 0-800-917-4256 (UK)**.

A replay of the call will also be available for ninety days on the company website.

Elron Electronic Industries Ltd. is a high technology holding company based in Israel. Through affiliates, Elron is engaged with a group of high technology operating companies in the fields of medical devices, information and communications technology, semiconductors and advanced materials. For further information, visit http://www.elron.com

Contact:

Rinat Remler Elron Electronic Industries Ltd. Tel. 972-3-6075555 rinat@elron.net

Any statements in this press release that may be considered forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Actual results may differ from such forward-looking statements due to the risk factors discussed in periodic reports filed by the Company with the Securities and Exchange Commission, which the Company urges investors to consider.

Tables to follow

CONDENSED CONSOLIDATED BALANCE SHEETS

In thousands of U.S. Dollars

in thousands of U.S. Donars	June 30, 2006 Unaudited	December 31, 2005
ASSETS Total current assets	\$ 133,857	\$ 155,201
INVESTMENTS AND LONG-TERM RECEIVABLES Investments in affiliated companies Investments in other companies and long-term receivables Deferred taxes Severance pay deposits	97,633 82,063 6,374 2,290	102,780 73,931 6,521 1,971
Total Investments and long-term Receivables	188,360	185,203
PROPERTY AND EQUIPMENT, NET	8,043	7,809
INTANGIBLE ASSETS	5,551	5,560
Total assets	\$ 335,811	\$ 353,773
LIABILITIES AND SHAREHOLDERS' EQUITY Total current liabilities	\$ 16,651	\$ 19,044
LONG-TERM LIABILITIES Long-term loans from banks and others Accrued severance pay and retirement obligations Deferred taxes	3,439 3,179 8,343	1,477 2,635 9,494
Total long-term liabilities	14,961	13,606
MINORITY INTEREST	12,777	19,007
Total Shareholders' Equity	291,422	302,116
Total liabilities and shareholders' equity	\$ 335,811	\$ 353,773

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

In thousands of U.S. Dollars, except share and per share data

•	Six months ended		Three mor	Year ended December	
	June	30,	Jun	31,	
	2006	2005	2006	2005	2005
		Unau	dited		
INCOME					
Net revenues Equity in losses of affiliated companies Gain (loss) from disposal of businesses and affiliated companies and changes in holdings in affiliated companies,	\$ 7,138 (11,866)	\$ 6,246 (7,827)	\$ 3,816 (8,371)	\$ 3,261 (4,244)	\$ 12,646 (17,522)
net	(7)	22,389	(23)	22,399	23,328
Other income, net	3,367	56,533	738	56,255	58,648
Financial income, net	2,280	4,267	1,196	3,370	5,483
	912	81,608	(2,644)	81,041	82,583
COSTS AND EXPENSES	17,788	12,085	9,274	6,520	26,097
Income (loss) before taxes on income Tax benefit (Taxes on income)	(16,876) (99)	69,523 (25,867)	(11,918) 183	74,521 (26,034)	56,486 (10,461)
Income from continuing operations after taxes on income Minority interest in losses of subsidiaries	(16,975) 7,037	43,656 645	(11,735) 5,310	48,487 451	46,025 5,160
Income from continuing operations Loss from discontinued operations	(9,938)	44,301 (2,214)	(6,425)	48,938 (1,738)	51,185 (3,850)
Net income (loss)	(9,938)	42,087	(6,425)	47,200	47,335
Income (loss) per share: Basic: Income (loss) from continuing					
operations Loss from discontinued operations	(0.34)	1.51 (0.08)	(0.22)	1.66 (0.06)	1.74 (0.13)
Net income (loss)	(0.34)	1.43	(0.22)	1.60	1.61
Diluted: Income (loss) from continuing operations	(0.35)	1.49	(0.22)	1.66	1.73
Loss from discontinued operations		(0.07)		(0.06)	(0.13)
Net income (loss)	(0.35)	1.42	(0.22)	1.60	1.60
Weighted average number of ordinary shares used in computing basic net income per share (thousands)	29,523	29,415	29,532	29,416	29,437
Weighted average number of ordinary shares used in computing diluted net income per share (thousands)	29,523	29,543	29,532	29,538	29,550

MANAGEMENT REPORT FOR THE SECOND QUARTER ENDED JUNE 30, 2006

The following discussion should be read in conjunction with our Condensed Interim Consolidated Financial Statements as of June 30, 2006 and notes thereto and with our Annual Consolidated Financial Statements as of December 31, 2005 and notes thereto, filed with the Securities and Exchange Commission under item 18 to our annual report on Form 20-F for the year ended December 31, 2005 ("2005 20-F"). This report contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements may be identified by the words "anticipate", "believe", "estimate", "expect", "plan" and similar expressions. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those discussed in our filings with the Securities and Exchange Commission from time to time.

OVERVIEW

We are a high technology operational holding company that operates through subsidiaries and affiliated companies, referred to as our group companies. Founded in 1962, we have been a major force in the development of the Israeli high technology industry by building Israeli and Israel-related companies with technologies in the fields of medical devices, communications, semiconductors, software products and services and advanced materials.

Our group companies include both publicly traded and privately held companies.

Our activities range from operational control over the business to involvement in the management of our group companies in which we maintain controlling or significant holdings, and, in a limited number of cases, non-significant holdings. We participate in the management of most of our group companies by means of active membership on their boards of directors and board committees. As a result, we are involved in matters of policy, strategic planning, marketing, selecting and manning senior management positions, approving investments and budgets, financing and the overall ongoing monitoring of our group companies' performance. In addition to our representation on the boards of directors of our group companies, we provide hands-on assistance to the group companies' management in support of their growth. We view our hands-on involvement in the operations of our group companies as a key element of our business. Our group companies therefore benefit from the experience of our management team in various areas in which they need support and leadership, including, but not limited to, strategic planning, research and development guidance, identifying joint venture opportunities, introductions to potential customers and investors, risk management, market analysis, business plan preparation, budgetary control, and legal support.

Technology industries are characterized by the high degree of risk inherent in their products, their continuous technological innovation and their penetration into world markets, which requires investment of considerable resources and continuous development efforts. The future success of our group companies is dependent upon their technological quality, prices and nature of their products in comparison to their competitors and their ability to introduce new products to the markets at the right time, while offering cost effective solutions suitable to their customers' needs as well as their ability to raise financing and the condition of the capital markets.

We expect to continue to build and realize value for our shareholders through the sale to third parties of a portion or all of our holdings in, or the issuance of shares by, our group companies, while simultaneously pursuing the acquisition of, or investment in, new and existing companies at different stages of development including early stage and more mature companies. We believe that this strategy provides the ability to increase shareholder value as well as to create capital to support the growth of our group companies and to invest in new opportunities. The nature of our business, therefore, will result in some volatility in our results of operations, depending on the transactions that occur within a particular period.

Our net income (or loss) in any given period is due, for the most part, to the results of operations of those of our group companies which are accounted by us under the consolidation or equity method of accounting and dispositions and changes in our holdings of group companies. As most of our group companies are technology companies which have not yet generated significant revenues and which invest considerable resources in research and development and in marketing activities, we have experienced, and expect to continue to experience, losses in respect of these companies to the extent they are accounted by us under the consolidation or equity method of accounting.

Our capital resources in any given period are primarily affected by the extent of our investment in existing and new companies and the realization of certain holdings as well as the impact of any dividends or distributions to our shareholders. The results of operations of our group companies, and consequently, our results of operations and capital resources, are affected by general economic conditions as well as by factors specifically related to the technology markets, which also affect the ability of our group companies to raise financing and our ability to dispose of holdings and realize gains from our holdings.

As of July 2006, Israel has been engaged in a military confrontation with Hezbollah in Lebanon, in which densely populated areas in northern Israel are coming under missile attack. This state of affairs has negative consequences for the economic situation, mainly in directly affected geographical areas. If this situation continues or worsens, it may adversely affect the Israeli business sector and negatively impact on our group companies' results of operation. Currently, the impact on our group companies, if any, has not been significant.

TREND INFORMATION

Technology industries are affected by economic trends and the condition of the capital markets. Since the second half of 2003, there has been a recovery in the technology sectors and capital markets from the downturn which commenced in 2001. This trend was reflected in the improvement in the results of operations of most of our group companies as well as the raising of funds from new strategic and other investors in private placements completed by some of our group companies. In addition, we recorded significant gains from realizing certain of our holdings, mainly in 2004 as a result of the sale of our holdings in Elbit Systems Ltd. (Nasdaq: ESLT) ("Elbit Systems"), and in the second quarter of 2005 from the sale of most of our shares in Partner Communications Company Ltd. (Nasdaq: PTNR) ("Partner") and the sale of all of our shares in Oren Semiconductor, Inc. ("Oren"). Total proceeds from these transactions amounted to approximately \$310 million. We have used the proceeds to distribute dividend of \$88.5 million to our shareholders and to continue investing in existing and new group companies. Since 2004 we invested \$55.5 million in 9 new companies. Should the improvement in the technology sectors and capital markets continue, we anticipate that it will have a positive effect on our group companies and their ability to raise additional capital.

NEW INVESTMENTS

Investment in Safend Ltd. ("Safend"). On January 2, 2006, we completed an investment of approximately \$3.7 million in Safend, as part of an aggregate investment of approximately \$7.4 million, in consideration for approximately 22% of Safend's equity on a fully diluted basis and on an as converted basis. Safend is an Israeli company which develops comprehensive desktop and laptop endpoint security solutions.

Investment in NuLens Ltd. ("NuLens"). On March 9, 2006 we made an additional investment of approximately \$1.5 million in NuLens, an Israeli medical device company operating in the field of intra-ocular lenses, mainly for cataract and presbyopia procedures. Our investment was part of an aggregate new investment of approximately \$6.0 million, led by Warburg Pincus, a leading global private equity fund. Simultaneously with this round we invested the second installment of our April 2005 first investment in NuLens, amounting to \$1.1 million. Following the above investments, we hold 25% of NuLens' equity, on a fully diluted and on an as converted basis.

Investment in AMT. In June 2006, AMT completed a financing round of \$14 million led by Shamrock Israel Growth Fund, an Israeli private equity fund. We committed to invest an amount of \$5 million in two installments; the first of \$2.5 million was invested immediately, and an additional \$2.5 million is subject to certain conditions. In addition, we and other shareholders converted into equity previously granted loans in the amount of \$1.0 million, of which our share was \$0.5 million. Following the above investment, our holdings in AMT decreased from approximately 42% to 34% on a fully diluted, as converted basis.

Purchase of Given Imaging Shares. Subsequent to the balance sheet date, we purchased approximately 540 thousand shares of Given Imaging for an aggregate purchase consideration of approximately \$10 million. As a result, our direct and indirect (through RDC) interest in Given Imaging increased from approximately 19.3% to approximately 21.2% of the outstanding shares of Given Imaging. Discount Investment Corporation ("DIC"), a 48% shareholder of Elron, simultaneously purchased the same number of shares of Given Imaging for the same aggregate consideration and now owns 14.3% of the outstanding shares of Given Imaging.

CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS

See our 2005 20-F under Item 10 "Additional Information – Taxation – U.S. Federal Income Tax Considerations - Tax Consequences if we are a Passive Foreign Investment Company ("PFIC")", concerning Elron's status with respect to the U.S. tax provisions regarding PFIC.

CRITICAL ACCOUNTING POLICIES

We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States ("US GAAP"). Our significant accounting policies are more fully described in Note 2 of the Notes to our 2005 Annual Consolidated Financial Statements. The accounting policies which are particularly important to the assessment of our financial position and results of operations are described under item 5 to our 2005 20-F under "Critical Accounting Policies".

BASIS OF PRESENTATION

Consolidation. Our consolidated financial statements include the accounts of Elron and all of our direct or indirect (through Elbit and DEP) controlled subsidiaries. The following are our main subsidiaries:

Three and six months ended June 30,

	2006	2005							
RDC	Starling		Elron TeleSoft ¹	SELA					
Galil Medical	3DV		RDC	3DV					
SELA	Medingo ²	Enure ³	Galil Medical	Starling					

¹ Sold on December 29, 2005.

Equity Method. Our main group companies held by us or through Elbit, DEP, Galil Medical and/or RDC accounted for under the equity method of accounting include:

Three and six months ended June 30.

	2006		2005						
Given Imaging	Wavion	CellAct	Given Imaging	ChipX	Pulsicom				
Oncura	AMT		Oncura	Wavion	CellAct				
NetVision	Notal Vision		NetVision	AMT					
ChipX	Pulsicom		Oren Semiconductor ¹	Notal Vision					

¹ Sold on June 10, 2005.

Other investments. Our main group companies held by us which are accounted for under the cost method or as available-for- sale as of June 30, 2006 include:

Cost - Jordan Valley, Teledata, Impliant, BrainsGate, NuLens and Safend.

Available-for-sale Securities – Partner and EVS.

RESULTS OF OPERATIONS

Three and six months ended June 30, 2006 compared to three and six months ended June, 2006.

The following tables set forth our results of operations in the reported period:

	Three months en	ided June 30,	Six months end	l June 30,	
	2006	2005	2006	2005	
		(millions of \$, excep	t per share data)		
Net income	(6.4)	47.2	(9.9)	42.1	
Net loss per share	(0.22)	1.60	(0.34)	1.43	

The net loss we reported in the three and six months ended June 30, 2006 resulted from our share in the net loss of our group companies in the amount of \$7.0 million and \$12.0 million, respectively, which included an amount of \$2.5 million, being our share in the impairment charge in Galil Medical's investment in Oncura, and from the absence of gains from sales of our share of group companies in both periods.

The net income we reported in the second quarter of 2005 was mainly due to the following gains from changes in holding and dispositions of group companies:

- (i) a gain, net of tax, of approximately \$36.0 million resulting from the sale of Partner's shares in consideration for \$94.0 million;
- (ii) a gain, net of tax, of approximately \$17.2 million resulting from the sale of Oren's shares in consideration for \$20.3 million in cash and Zoran shares; and
- (iii) a gain of approximately \$3.0 million from the decrease in our interest in NetVision following its initial public offering.

The above gains were offset by losses, net, which we recorded with respect to our group companies in the three and six month periods ended June 30, 2005 in the amount of \$7.4 million and \$12.2 million, respectively.

² Medingo was established by RDC in the fourth quarter of 2005.

³ Enure (formerly known as Gaia Broadband Services Management Ltd.) has been consolidated since its acquisition, in the beginning of the fourth quarter of 2005.

The following table summarizes our operating results:

	Three months end	ed June 30,	Six months end	ed June 30,
	2006	2005	2006	2005
		(millions	of \$)	
Net revenues	3.8	3.3	7.1	6.2
Net loss from equity investments	(8.4)	(4.2)	(11.9)	(7.8)
Gains from disposal of business and affiliated companies and				
changes in holdings in affiliated companies	=	22.4	-	22.4
Other income, net	0.7	56.2	3.4	56.5
Finance income, net	<u>1.2</u>	<u>3.3</u>	<u>2.3</u>	<u>4.3</u>
Total income	(2.6)	<u>81.0</u>	<u>0.9</u>	<u>81.6</u>
Cost of revenues	2.0	2.1	3.9	4.0
Operating expenses(**)	7.3	4.3	13.9	7.9
Amortization of other assets	<u>=</u>	<u>0.1</u>	<u>=</u>	<u>0.1</u>
Total costs and expenses	<u>9.3</u>	<u>6.5</u>	<u>17.8</u>	<u>12.0</u>
Gain (loss) from continuing operations before income taxes	(11.9)	74.5	(16.9)	69.6
Tax benefit (Income taxes)	0.2	(26.0)	(0.1)	(25.9)
Minority interest	<u>5.3</u>	<u>0.5</u>	<u>7.0</u>	<u>0.6</u>
Net income (loss) from continuing operations	(6.4)	48.9	(9.9)	44.3
Discontinued operations of the Elron Telesoft group (*)	<u>-</u>	<u>(1.7)</u>	Ξ	(2.2)
Net income (loss)	<u>(6.4)</u>	<u>47.2</u>	<u>(9.9)</u>	<u>42.1</u>

^{*} In December 2005, we sold all our holdings in the Elron Telesoft group which was focused on telecom network management products and services, and accordingly the prior period results have been reclassified as discontinued operations.

Income

Net revenues. Net revenues consisted of sales of products and services by our subsidiaries, mainly Galil Medical and SELA. The following table sets forth these revenues:

	Three months en	ded June 30,	Six months ended June 30,						
	2006	2005	2006	2005					
	(millions of \$)								
Galil Medical	2.2	2.2	4.0	4.1					
SELA	1.5	1.1	3.0	2.0					
Other	<u>0.1</u>	<u>=</u>	<u>0.1</u>	<u>0.1</u>					
	<u>3.8</u>	<u>3.3</u>	<u>7.1</u>	<u>6.2</u>					

Galil Medical's revenues derived mainly from the supply of cryo products and R&D services to Oncura, in which it has a 25% ownership interest.

Share in net losses of affiliated companies. Our share in net losses of affiliated companies resulted from our holdings in certain investments that are accounted for under the equity method (see above under "Basis of Presentation"). Our share in net losses of affiliated companies amounted to \$8.4 million and \$11.9 million in the three and six months period ended June 30, 2006, compared to \$4.2 million and \$7.8 million in the same periods in 2005. Our share in the net losses of affiliated companies in the three and six months period ended June 30, 2006 included a \$6.1 million impairment charge in Galil Medical's investment in Oncura (\$2.5 million after minority interest).

Highlights of the Results of Operations of Our Major Affiliates:

Given Imaging (Nasdaq: GIVN) (a 19% holding directly and indirectly through RDC as of June 30, 2006). Given Imaging Ltd. ("Given Imaging"), a medical device company that develops, manufactures and markets innovative diagnostic systems for visualizing the gastrointestinal tract, using a disposable miniature swallowable video capsules, recorded revenues of \$23.2 million and \$43.5 million in the three and six months period ended June 30, 2006 compared to \$20.5 million and \$42.5 million in the same periods in 2005. Given Imaging's net loss in the three and six months period ended June 30, 2006 was \$0.7 million and \$3.7 million, compared to net loss of \$0.4 million and net income of \$0.9 million in the same periods in 2005. The net loss in the three and six months period ended June 30, 2006 includes the impact of \$1.7 million and \$3.0 million in compensation expenses due to the impact of FAS 123R, which was adopted by Given Imaging as of the beginning of 2006.

^{**} Excluding amortization of intangible assets which are presented separately.

Oncura (a 25% holding by Galil). Oncura, which markets and sells therapeutic device systems and related consumables used primarily in the performance of minimally-invasive, urologic cancer treatment, recorded revenues in the three and six months period ended June 30, 2006 of approximately \$16.1 million and \$32.7 million, compared to \$20.0 million and \$38.4 million in the same periods in 2005. Oncura's net loss in the three and six months period ended June 30, 2006 amounted to \$1.7 million and \$3.4 million, compared to \$1.3 million and \$2.2 million in the same periods in 2005. The increase in the net loss resulted primarily due to the decrease in revenues. In light of Oncura's results of operations, an impairment charge of \$6.1 million was recorded in the second quarter of 2006 (\$2.5 million after minority interest). In August 2006 Oncura's shareholders provided to Oncura a letter in which they confirmed their intention to continue providing financial support to Oncura through August 2007 or such later date, as may be agreed by Oncura's shareholders.

NetVision (a 39% holding) (TASE: NTSN). NetVision provides Internet services and solutions in Israel and commencing the fourth quarter of 2004 international telephony services through Voice over IP technology (VoIP). NetVision's revenues in the three and six months ended June 30, 2006 increased by 21% and 17% to \$22.9 million and \$43.6 million from \$18.9 million and \$37.3 million in the same periods in 2005 and its customer base at June 30, 2006 reached approximately 437,000 (of which approximately 293,000 were broadband) compared to 425,000 at the end of 2005 (of which approximately 272,000 were broadband). NetVision's operating income in the three and six months periods ended June 30, 2006 increased by 32% and 62% to \$3.6 million and \$6.2 million, compared to \$2.7 million and \$3.9 million in the same periods in 2005, mainly as a result of the increase in Internet services operating income, and its net income increased in the three and six months period ended June 30, 2006 to \$2.9 million and \$4.8 million from \$1.2 million and \$1.4 million in the same period in 2005. NetVision's operating currency is the New Israeli Shekel (NIS) and accordingly, all figures above are translations for convenience purposes of NetVision's NIS figures into US dollars at the representative rate of exchange prevailing at June 30, 2006 according to which \$1.00 equaled NIS 4.44.

On May 1, 2006, NetVision announced that it will be entering into merger discussions with Barak I.T.C. (1995) International Telecommunications Services Corp. Ltd ("Barak"), a subsidiary of Clal Industries and Investments Ltd. ("Clal"). Elron, Clal and DIC, the other major shareholder of NetVision, are all part of the IDB group. Barak engages mainly in the provision of international telecommunication services. On July 30, NetVision announced that certain basic understandings have been reached, whereby NetVision would purchase all of Barak's issued share capital in exchange for approximately 47% of NetVision's share capital immediately after the transaction. In addition, NetVision and DIC are negotiating a transaction whereby NetVision would purchase all of the issued share capital of GlobeCall Communications Ltd. ("GlobeCall") from DIC in exchange for NetVision shares, which would represent approximately 7% of NetVision's issued share capital immediately following both transactions. The abovementioned exchange ratios were based upon drafts of company valuations, that were issued to the parties by independent appraisers, according to which NetVision's valuation was estimated to be between 540 million NIS (approximately \$122 million) and 620 million NIS (approximately \$140 million), Barak's valuation was estimated to be between 470 million NIS (approximately \$16 million) and 90 million NIS (approximately \$20 million). The GlobeCall transaction would close immediately after the Barak transaction, and is dependent upon it.

If these transactions occur, our holding in NetVision would be reduced to approximately 19%.

The transaction, if it takes place, will be subject to the signing of a definitive agreement as well as corporate and regulatory approvals. There is no assurance that the transactions will be consummated.

Wavion (a 38% holding). Wavion is a developer of broadband wireless access systems for Wi-Fi networks. Wavion's net loss amounted to \$1.8 million and \$3.8 million in the three and six month periods ended June 30, 2006 compared to \$1.5 million and \$3.1 million in the same periods in 2005. The increase in Wavion's loss resulted mainly from increase in Wavion's marketing expenses relating to the launch of its product. In May 2006, Wavion completed a private placement of \$3.6 million from existing shareholders.

ChipX (a 29% holding as of June 30, 2006). ChipX is a manufacturer of late stage programmable application-specific integrated circuits, or structured ASICs. ChipX's revenues in the three and six month periods ended June 30, 2006 amounted to \$3.8 million and \$7.3 million, compared to \$4.0 million and \$9.0 million in the same periods in 2005, and its net loss amounted to \$1.5 million and \$3.2 million, compared to \$1.3 million and \$1.8 million in the same periods in 2005. Revenues decreased as ChipX shifted from its old product to the new Structured ASIC products. In May 2006, ChipX completed a private placement of \$6.0 million from existing shareholders, the proceeds of which will be used to finance its sales and marketing activities. We invested approximately \$2.3 million in this round resulting in the increase in our interest in ChipX to 26%, on a fully diluted basis.

AMT (a 34% holding). The AMT group develops technologies and products based on amorphous metals. AMT's consolidated revenues in the three and six month periods ended June 30, 2006, amounted to \$0.9 million and \$1.7 million, compared to \$1.1 million and \$1.8 million in the same periods in 2005 and its consolidated net loss amounted to \$1.7 million and \$3.1 million in the three and six month periods ended June 30, 2006, compared to \$0.6 million and \$1.4 million in the same period in 2005.

We expect that most of our group companies as well as new companies in which we will invest will continue to recognize losses in future periods, as they invest significant resources in research and development and sales and marketing activities and have not yet

generated significant revenues. Our results of operations will therefore be affected by the extent of our share in their net losses (to the extent they are reported under the equity or consolidation method of accounting).

Gains from Disposal of Businesses and Affiliated Companies and Changes in Holdings in Affiliated Companies. No gains from disposal of businesses and affiliated companies and changes in our holdings in affiliated companies were reported in the three and six months period ended June 30, 2006. Gains from disposal of businesses and affiliated companies and changes in our holdings in affiliated companies amounted in both of the three and six months period ended June 30, 2005 to \$22.4 million. The gain in the three and six months period ended June 30, 2005 resulted primarily from the following: (i) a gain of approximately \$19.7 million (which after income taxes amounted to \$17.2 million) resulting from the sale of Oren's shares in consideration for \$20.3 million; and (ii) a gain of approximately \$3.0 million from the decrease in our interest in NetVision following its initial public offering.

Other Income, *net*. Other income, net, amounted to \$0.7 million and \$3.4 million in the three and six months ended June 30, 2006 compared to \$56.3 million and \$56.5 million in the same periods in 2005. The gain for the three month periods ended June 30, 2006 resulted mainly from dividend distributed by Partner in the amount of \$1.0 million. The gain in six months period of 2006 also included a \$2.7 million gain resulting from the settlement of Mediagate's bank loan.

The gain in both of the three and six months period ended June 30, 2005 was primarily due to a \$56.4 million gain (which after income taxes amounted to \$36.0 million) from the sale of 12,765,190 shares of Partner for approximately \$94.0 million.

Finance income, *net*. Finance income, net, in the three and six months ended June 30, 2006 amounted to \$1.2 million and \$2.2 million, compared to \$3.3 million and \$4.3 million in the same periods in 2005. The decrease in finance income is mainly due to lower cash and debenture balances during the first half of 2006 as compared to the first half of 2005.

Expenses

Cost of revenues. Cost of revenues consisted primarily of expenses related to salaries and hardware associated with delivering products and services of our subsidiaries, mainly Galil Medical and SELA. Cost of revenues in the three and six months period ended June 30, 2006 amounted to \$2.0 million and \$3.9 million, compared to \$2.1 million and \$4.0 million in the same periods in 2005.

Operating expenses. Operating expenses are comprised of research and development expenses, sales and marketing and general and administrative expenses of our and RDC's corporate operations and of our subsidiaries, mainly Galil Medical, SELA, Starling, Enure, Medingo and 3DV. The following table sets forth the operating expenses:

	Three months ende	ed March 31	Six months ended June 30			
	2006	2006 2005 2006		2005		
		(millions o	of \$)			
Corporate	1.6	2.1	3.3	3.9		
Galil Medical	0.8	0.5	1.5	1.2		
SELA	1.0	0.8	2.1	1.6		
Starling	1.1	0.6	2.3	1.0		
3DV	0.8	0.6	1.5	0.9		
Enure*	0.9	-	1.4	-		
Medingo*	0.7	-	1.2	-		
RDC	<u>0.3</u>	(0.3)	<u>0.6</u>	<u>(0.7)</u>		
	<u>7.3</u>	<u>4.3</u>	<u>13.9</u>	<u>7.9</u>		

^{*} Consolidated since the forth quarter of 2005.

Corporate operating expenses in the three and six months ended June 30, 2006 amounted to \$1.6 million and \$3.3 million, compared to \$2.1 million and \$3.9 million in the comparable periods of 2005. The decrease resulted mainly from a decrease in salaries and related expenses.

Operating expenses of Galil Medical in the three and six months ended June 30, 2006 amounted to \$0.8 million and \$1.5 million, compared to \$0.5 million and \$1.2 million in the same periods in 2005 and its operating results in the three and six months ended June 30, 2006 and 2005 were operating income of \$0.1 million and operating loss of \$0.1 million. Galil is currently focused on the development of the cryotherapy technology for application in the women's health field. In November 2005, Galil Medical's Cryo products received FDA clearance for the treatment of breast fibroadenoma (non cancerous breast lumps).

SELA's operating expenses amounted to \$1.0 million and \$2.1 million in the three and six months ended June 30, 2006, compared to \$0.8 million and \$1.6 million in the same periods in 2005 and its operating loss amounted to \$0.2 million and \$0.4 million, the same as in the comparable periods in 2005.

Starling's operating expenses and operating loss amounted to \$1.1 million and \$2.3 million in the three and six months ended June 30, 2006, compared to \$0.6 million and \$1.0 million in the same periods in 2005. The increased loss resulted mainly from the increase in development expenses.

LIQUIDITY AND CAPITAL RESOURCES

Consolidated cash, debentures and deposits at June 30, 2006, were approximately \$122.7 million compared with \$143.8 million at December 31, 2005. At June 30, 2006, corporate cash, debentures and deposits were \$113.8 million compared with \$133.8 million at December 31, 2005.

The main uses of the corporate cash and other liquid instruments in the first half of 2006, were \$21.1 million of investments in our group companies, which included the purchase of additional 0.6% of Partner shares from one of the other Israeli founding shareholders of Partner for approximately \$5.3 million, a \$3.5 million investment in Safend, a \$2.6 million investment in Nulens, a \$2.3 million investment in ChipX, a \$2.5 million investment in AMT, a \$2 million loan to our subsidiary RDC, and a \$1.4 million investment in Wavion.

Consolidated working capital at June 30, 2006 amounted to \$117.2 million compared to \$136.2 million at December 31, 2005. The decrease is mainly due to the decrease in corporate cash and other liquid instruments.

Consolidated loans at June 30, 2006, were approximately \$6.3 million, compared to \$7.3 million at December 31, 2005. In the first quarter of 2006 MediaGate's bank loan in the amount of approximately \$2.8 million was settled in consideration for \$0.1 million.

Almost all of the Partner shares held by us as of June 30, 2006, amounting to approximately 3.9 million shares, are subject to certain transfer restrictions under Partner's Israeli communications license.

Subsequent to the balance sheet date, we purchased approximately 540 thousand shares of Given Imaging in the aggregate amount of approximately \$10 million.

Our investment policy for managing our funds is in general to invest in bank deposits and U.S. government securities with high liquidity.

We believe that our existing capital will be sufficient to fund our and our subsidiaries' operations and our investment plan in existing and new companies for at least the next twelve months.

Shareholders' equity at June 30, 2006, was approximately \$291.4 million, representing approximately 87% of the total assets compared with \$302.1 million representing approximately 85% of total assets at December 31, 2005.

#

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2006 (Unaudited)

CONDENSED INTERIM CONSOLIDATED

FINANCIAL STATEMENTS

AS OF JUNE 30, 2006

UNAUDITED

INDEX

	Page
Consolidated Balance Sheets	1-2
Consolidated Statements of Operations	3
Statements of Shareholders' Equity	4-5
Consolidated Statements of Cash Flows	6-7
Notes to the Consolidated Financial Statements	8-13
Annex to the Consolidated Financial Statements	14

.

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands, except share and per share data

	June 30, 2006 Unaudited		De	ecember 31, 2005
ASSETS CURRENT ASSETS Cash and cash equivalents Short-term investments Available-for-sale marketable debentures Trade receivables (net of allowance for doubtful accounts of \$5 and of \$426 at June 30, 2006 and at December 31, 2005)* Other receivables and prepaid expenses* Inventories	\$	38,290 25,684 58,685 6,399 2,730 2,069	\$	26,520 54,661 62,617 6,440 2,846 2,117
Total current assets		133,857		155,201
INVESTMENTS AND LONG-TERM RECEIVABLES Investments in affiliated companies Investments in other companies and long-term receivables* Deferred taxes Severance pay deposits		97,633 82,063 6,374 2,290		102,780 73,931 6,521 1,971
Total investments and long-term receivables		188,360		185,203
PROPERTY AND EQUIPMENT, NET		8,043		7,809
INTANGIBLE ASSETS Goodwill Other intangible assets		2,742 2,809		2,742 2,818
Total intangible assets		5,551		5,560
Total assets	\$	335,811	\$	353,773

^{*} Includes short term receivables from related parties in the aggregate amount of \$5,158 and \$5,043 as of June 30, 2006 and December 31, 2005, respectively, and long term receivables from related parties in the aggregate amount of \$450 and \$434 as of June 30, 2006 and December 31, 2005, respectively.

CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands, except share and

U.S. dollars in thousands, except share and per share data				
	June 30, 2006 Unaudited		De	ecember 31, 2005
LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Short-term loans from banks Current maturities of long-term loans from banks and others Trade payables Other payables and accrued expenses	\$	700 2,141 2,335 11,475	\$	3,808 2,065 2,146 11,025
Total current liabilities		16,651		19,044
LONG-TERM LIABILITIES Long-term loans from banks and others Accrued severance pay and retirement obligations Deferred taxes		3,439 3,179 8,343		1,477 2,635 9,494
Total long-term liabilities MINORITY INTEREST		14,961 12,777		13,606 19,007
SHAREHOLDERS' EQUITY: Ordinary shares of NIS 0.003 par value; Authorized - 35,000,000 shares as of June 30, 2006 and December 31, 2005; Issued and outstanding - 29,531,955 and 29,483,455 shares as of June 30, 2006 and as of December 31, 2005, respectively. Additional paid-in capital Accumulated other comprehensive income Retained earnings		9,572 271,564 9,553 733		9,572 271,132 10,741 10,671
Total shareholders' equity		291,422		302,116
Total liabilities and shareholders' equity	\$	335,811	\$	353,773

CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands, except share and per share data

, <u>-</u>	Six months ended June 30,		Three months ended June 30,				Year ended December 31,			
		2006		2005***		2006		2005***		2005
				Una	udite	ed				
INCOME										
Net revenues*	\$	7,138	\$	6,246	\$	3,816	\$	3,261	\$	12,646
Equity in losses of affiliated companies		(11,866)		(7,827)		(8,371)		(4,244)		(17,522)
Gain (loss) from disposal of businesses and affiliated companies and changes in										
holdings in affiliated companies, net		(7)		22,389		(23)		22,399		23,328
Other income, net		3,367		56,533		738		56,255		58,648
Financial income, net		2,280		4,267		1,196		3,370		5,483
		912		81,608		(2,644)		81,041		82,583
Costs of revenues		2 962		2.060		2.017		2.005		7.007
Cost of revenues		3,862 5 979		3,960		2,017 2,970		2,085		7,907
Research and development costs, net Marketing and selling expenses, net		5,878 2,128		2,643 1,089		1,253		1,409 620		6,163 2,386
General and administrative expenses		5,911		4,248		3,030		2,296		9,249
Amortization of intangible assets		9		145		3,030 4		110		392
Amortization of intaligione assets		17,788	_	12,085	_	9,274		6,520		26,097
Income (loss) before taxes on income		(16,876)		69,523		(11,918)		74,521		56,486
Tax benefit (Taxes on income)		(99)		(25,867)		183		(26,034)		(10,461)
Income (loss) after taxes on income		(16,975)		43,656		(11,735)		48,487		46,025
Minority interest in losses of subsidiaries		7,037		645		5,310		451		5,160
Income (loss) from continuing operations		(9,938)		44,301		(6,425)		48,938		51,185
Loss from discontinued operations**		-		(2,214)		-		(1,738)		(3,850)
Net income (loss)	\$	(9,938)	\$	42,087	\$	(6,425)	\$	47,200	\$	47,335
Income (loss) per share:										
Basic:		(0.0.1)				(0.00)			Φ.	1.51
Income (loss) from continuing operations Loss from discontinued operations	\$	(0.34)	\$	1.51 (0.08)	\$	(0.22)	\$	1.66 (0.06)	\$	1.74 (0.13)
Net income (loss)	\$	(0.34)	\$	1.43	\$	(0.22)	\$	1.60	\$	1.61
Diluted:	Ψ	(0.54)	<u> </u>	11.10	Ψ	(0.22)	=	1.00	Ψ	1.01
Income (loss) from continuing operations	\$	(0.35)	\$	1.49	\$	(0.22)	\$	1.66	\$	1.73
Loss from discontinued operations	Ψ	-	Ψ	(0.07)	Ψ	-	Ψ	(0.06)	Ť	(0.13)
Net income (loss)	\$	(0.35)	\$	1.42	\$	(0.22)	\$	1.60	\$	1.60
Weighted average number of ordinary shares										
used in computing basic net income (loss)										
per share (thousands)		29,523	. <u></u>	29,415		29,532	. <u></u>	29,416		29,437
Weighted average number of ordinary shares										
used in computing diluted net income (loss)										
per share (thousands)	_	29,523		29,543	_	29,532		29,538		29,550

^{*} Includes revenues from related parties, in the amount of \$3,506 and \$ 3,967 for the six months ended June 30, 2006 and 2005, respectively, an amount of \$1,762 and \$2,144 for the three months ended June 30, 2006 and 2005, respectively, and an amount of \$8,046 for the year ended December 31, 2005.

^{**} Includes revenues from related parties in the amount of \$143 for the six months ended June 30, 2005, an amount of \$0 for the three months ended June 30, 2005, and an amount of \$174 for the year ended December 31, 2005.

^{***} Reclassified due to discontinued operations.

STATEMENTS OF SHAREHOLDERS' EQUITY

U.S. dollars in thousands, except share and per share data

_	Number of shares	Sh	are capital	Additional d-in capital	occumulated other mprehensive income	Retained earnings	Si	Total hareholders' equity		Total mprehensive acome (loss)
Balance as of January 1, 2005	29,414,424	\$	9,572	\$ 270,005	\$ 57,717	\$ 51,786	\$	389,080		
Exercise of options Stock - based compensation	69,031		-	697 405				697 405		
Tax benefit in respect of options exercised	-		-	25	-	-		25		
Dividend paid				23		(88,450)		(88,450)		
Other comprehensive loss, net of tax:						(,,		(,,		
Unrealized loss on available for sale securities	-		-	-	(10,450)	-		(10,450)	\$	(10,450)
Reclassification adjustment for gain realized and other than										
temporary impairment included in net income	-		-	-	(36,335)	-		(36,335)		(36,335)
Foreign currency translation adjustments Net income	-		-	-	(191)	47,335		(191) 47,335		(191) 47,335
-				 	 	 *		•		47,333
Balance as of December 31, 2005	29,483,455	\$	9,572	\$ 271,132	\$ 10,741	\$ 10,671		302,116	_	
Total comprehensive income									\$	359
Unaudited	40.500			2.42				2.12		
Exercise of options Stock - based compensation	48,500		-	242 190	-	-		242 190		
Other comprehensive income (loss), net of tax:	-		-	190	-	-		190		
Unrealized loss on available for sale securities	_		_	_	(1,832)	_		(1,832)	\$	(1,832)
Reclassification adjustment for loss realized and other than					((, ,		() /
temporary impairment included in net loss	-		-	-	386	-		386		386
Foreign currency translation adjustments	-		-	-	258	-		258		258
Net loss				 	 	 (9,938)		(9,938)		(9,938)
Balance as of June 30, 2006	29,531,955	\$	9,572	\$ 271,564	\$ 9,553	\$ 733	\$	291,422	:	
Total comprehensive loss									\$	(11,126)
Unaudited										
Balance as of January 1, 2005	29,414,424	\$	9,572	\$ 270,005	\$ 57,717	\$ 51,786	\$	389,080		
Exercise of options	2,500		-	19 163	-	-		19 163		
Stock based compensation Other comprehensive loss, net of tax:	-		-	163	-	-		103		
Unrealized loss on available-for-sale securities	_		_	_	(13,252)	_		(13,252)	\$	(13,252)
Reclassification adjustment for gain realized included in net					(13,232)			(13,232)	Ψ	(13,232)
income	-		-	-	(36,365)	-		(36,365)		(36,365)
Foreign currency translation adjustments	-		-	-	(163)	-		(163)		(163)
Net income			-	 -	 -	 42,087		42,087		42,087
Balance as of June 30, 2005	29,416,924	\$	9,572	\$ 270,187	\$ 7,937	\$ 93,873	\$	381,569	:	
Total comprehensive loss									\$	(7,693)

STATEMENTS OF SHAREHOLDERS' EQUITY

U.S. dollars in thousands, except share and per share data

	Number of shares	Sha	are capital		Additional id-in capital	con	cumulated other nprehensive income		Retained earnings ccumulated deficit)	S	Total hareholders' equity	Total mprehensive acome (loss)
Unaudited Balance as of April 1, 2006	29,531,955	\$	9,572	\$	271.468	\$	9.428	\$	7,158	\$	297.626	
Stock based compensation	-	·	-		96		-		-		96	
Other comprehensive income (loss), net of tax:												
Unrealized loss on available for sale securities	-		-		-		(352)		-		(352)	\$ (352)
Reclassification adjustment for loss realized included in net loss							144				144	144
and other than temporary impairment included in net loss Foreign currency translation adjustments	_		-		_		144 333		_		144 333	144 333
Net loss	_	_	_	_	_	_	-		(6,425)		(6,425)	(6,425)
•									(0,1=0)	-	(0,1=0)	(0,120)
Balance as of June 30, 2006	29,531,955	\$	9,572	\$	271,564	\$	9,553	\$	733	\$	291,422	
Total comprehensive loss										-		\$ (6,300)
												<u>.</u>
Unaudited	20 41 4 42 4	œ.	0.570	Φ.	270 114	Φ.	62,000	Ф	46.672	Φ.	200 420	
Balance as of April 1, 2005 Exercise of options	29,414,424 2,500	\$	9,572	\$	270,114 19	\$	63,080	\$	46,673	\$	389,439 19	
Stock based compensation	2,300		-		54		-		-		54	
Other comprehensive loss, net of tax:					31						5.	
Unrealized losses on available-for-sale securities	-		-		_		(18,586)		-		(18,586)	\$ (18,586)
Reclassification adjustment for gain realized included in net												
income	-		-		-		(36,365)		-		(36,365)	(36,365)
Foreign currency translation adjustment	-		-		-		(192)		47.200		(192)	(192)
Net income									47,200		47,200	 47,200
Balance as of June 30, 2005	29,416,924	\$	9,572	\$	270,187	\$	7,937	\$	93,873	\$	381,569	
Total comprehensive loss												\$ (7,943)

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands	Six n ended	Year ended December 31,	
	2006	2005	2005
		udited	2005
Cash flows from operating activities			¢ 47.225
Net income (loss) Adjustments to reconcile net income to net cash used in operating activities:	\$ (9,938)	\$ 42,087	\$ 47,335
Equity in losses of affiliated companies	11,866	7,827	17,522
Minority interest in losses of subsidiaries	(7,037)	(645)	(5,160)
Loss (gain) from disposal of businesses and affiliated companies and changes in	(7,037)	(043)	(3,100)
holdings in affiliated companies, net	7	(22,389)	(23,328)
Loss (gain) from sale of investments and other than temporary decline in	•	(==,= ==)	(==,===)
available for sale securities	341	(56,423)	(56,515)
Gain from settlement of a subsidiary's loan	(2,708)	-	-
Gain from disposal of business included in discontinued operations	-	-	(213)
Depreciation and amortization	551	690	1,513
Impairment of intangible assets (discontinued operations)	-	1,329	1,329
Decline in value of other investments	-	636	636
Equity in losses (gains) of partnerships	618	60	(174)
Stock-based compensation and changes in liability in respect of call options	611	(1,128)	(811)
Deferred taxes, net	(35)	(4,645)	(7,288)
Changes in operating assets and liabilities	41	(270)	(0.47)
Decrease (increase) in trade receivables	41 103	(278)	(947)
Decrease (increase) in other receivables and prepaid expenses Decrease in trading securities, net	103	(112) 1	(38)
Decrease (increase) in inventories and contracts—in-progress	48	(400)	(519)
Increase (decrease) in trade payables	189	(1,028)	(834)
Increase (decrease) in other payables and accrued expenses	273	12,854	(12,139)
Other	731	(368)	(753)
Net cash used in operating activities	(4,339)	(21,932)	(40,380)
Cash flows from investing activities	(1,557)	(21,552)	(10,500)
Investment in affiliated companies	(6,226)	(3,221)	(3,823)
Investment in other companies	(6,439)	(16,350)	(27,651)
Proceeds from sale of affiliated companies shares	992	10,076	10,522
Proceeds from repayment of loan granted to an affiliate company	-	2,253	2,253
Purchase of treasury stock from the minority by a subsidiary	-	(823)	(823)
Cash and cash equivalents resulting from newly consolidated subsidiaries (Sch. A)	-	-	-
Change in cash and cash equivalents resulting from disposal of business (Sch. B)	-	-	1,800
Proceeds from sale of available for sale securities	22,855	94,935	119,888
Proceeds from sale of other investments	-	93	237
Investments in deposits	(25,707)	(20,535)	(59,185)
Investment in available for sale securities	(24,668)	(18,405)	(35,405)
Proceeds from deposits	54,040 (790)	50,221	105,802
Purchase of property and equipment Proceeds from sale of property and equipment	15	(429) 120	(995) 197
Net cash provided by investing activities	14,072	97,935	112,817
Cash flows from financing activities	14,072	71,733	112,017
Proceeds from options exercised	242	19	697
Proceeds from exercise of options in a subsidiary	2-72	-	8
Repayment of long-term loans	(2)	(44)	(777)
Increase (decrease) in short-term bank loan, net	(400)	(76)	(1,079)
Receipt of short-term loans, convertible loans and long-term loans from minority	` ,	` /	(, ,
shareholders of a subsidiary	2,197	500	1,003
Issuance of shares to the minority of a subsidiary	-	145	145
Issuance expenses in a subsidiary	-	(67)	(75)
Dividend paid	-		(88,450)
Net cash provided by (used in) financing activities	2,037	477	(88,528)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	11,770	76,480	(16,091)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	26,520	42,611	42,611
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	\$ 38,290	\$ 119,091	\$ 26,520
LECCICACH AND CACHEOLINALENTS ATTRIBUTED TO DISCONTINUED OPERATIONS		(201)	
LESS CASH AND CASH EQUIVALENTS ATTRIBUTED TO DISCONTINUED OPERATIONS	38,290	(291) 118,800	26,520
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	30,290	110,000	20,320

2,389

(171)

213

\$ 1,800

\$ -

CONSOLIDATED STATEMENTS OF CASH FLOWS							
U.S. dollars in thousands							
	Six months ended June 30,				Year ended December 31		
		2006		2005	2005		
		Una	udited	<u> </u>			
Supplemental cash flow information: Cash paid for:	Φ.	<i>(</i> 72)	Φ	15.005	Φ	20.501	
Income taxes	\$	672	\$	15,025		30,591	
Interest	\$	42	\$	109	\$	203	
Proceeds from sale of an affiliate not yet received	\$	_	\$	2,392	\$	1,958	
Proceeds from sale of an affiliate received in Zoran shares	\$		\$	7,700	\$	7,700	
subsidiaries Assets acquired and liabilities assumed at the purchase date: Working capital deficiency, net (except cash and cash equivalents) Property and equipment Intangible assets Accrued severance pay, net Liability incurred	\$	- - - -	\$	- - - -	\$	75 (14) (237) 27 149	
Cash and cash equivalents acquired	\$		\$		\$	-	
SCHEDULE B:							
Change in cash and cash equivalents resulting from disposal of businesses							
Assets and liabilities at date of sale: Working capital deficiency, net (except cash and cash equivalents) Property and equipment	\$	- -	\$	-	\$	(671) 40 2 380	

The accompanying notes are an integral part of the consolidated financial statements.

Intangible assets

Accrued severance pay, net

Gain resulting from sale of businesses

Net increase in cash and cash equivalents

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 1:- GENERAL

The accompanying unaudited condensed interim consolidated financial statements have been prepared as of June 30, 2006, and for the three and six months then ended in accordance with accounting principles generally accepted in the United States (U.S. GAAP) relating to the preparation of financial statements for interim periods. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States but which are not required for interim reporting purposes, have been condensed or omitted. See Note 5 for the reconciliation from U.S. GAAP to accounting principles generally accepted in Israel ("Israeli GAAP").

These financial statements should be read in conjunction with the Company's annual financial statements and accompanying notes as of December 31, 2005, included in Form 20F for the year ended December 31, 2005 filed with the Securities and Exchange Commission ("the Company's annual financial statements").

The condensed interim consolidated financial statements reflect all adjustments which are, in the opinion of management considered, necessary to present fairly the financial position, results of operations and cash flows for the periods presented.

Results for the three and six months ended June 30, 2006 are not necessarily indicative of the results that may be expected for the year ending December 31, 2006.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

- a. The significant accounting policies followed in the preparation of these financial statements are identical to those applied in preparation of the latest annual financial statements, except as included in c below.
- b. The financial statements have been prepared in U.S. dollars, since the functional currency of the Company and its principal subsidiaries is the U.S. dollar.
- c. Effective January 1, 2006 ("the effective date") the Company applied SFAS No. 123(R), "Share-Base Payment", which revises the previously effective SFAS No. 123 and supersedes APB No. 25. Generally, the approach in SFAS 123(R) is similar to the approach described in SFAS 123. However, SFAS 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative.

The company, its subsidiaries and its affiliated companies adopted SFAS 123(R) using the modified-prospective method. According to the modified-prospective method, compensation cost is recognized beginning with the effective date (a) based on the grant date fair value estimated in accordance with the provisions of SFAS 123(R) for all share-based payments granted after the effective date and (b) based on the grant date fair value estimated in accordance with the provisions of SFAS 123 "Accounting for Stock-Based Compensation" ("SFAS 123") for all awards granted to employees prior to the effective date of SFAS 123(R) that remain unvested on the effective date.

Previously, the Company and its subsidiaries adopted the fair-value-based method of accounting based on the provisions of SFAS 123 for share-based payments effective January 1, 2003 using the prospective methods described in SFAS 148 "Accounting for Stock- Based Compensation- Transition and Disclosure".

Because 1) SFAS 123(R) must be applied not only to new awards but also to previously granted awards that are not fully vested on the effective date, 2) the Company adopted

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.)

c. (cont.)

SFAS 123 using the prospective transition method (which applied only to awards granted, modified or settled after January 1, 2003), and 3) prior to January 1, 2006, the Company's affiliated companies applied APB 25 whereby compensation cost measured based on the intrinsic value of the options granted, compensation cost for some previously granted awards in the Company, its subsidiaries and in its affiliated companies that were not previously recognized are recognized under SFAS 123(R).

As a result of adopting the provisions of SFAS 123(R) on January 1, 2006 by the Company, its subsidiaries and its affiliated companies, the Company recorded compensation expenses in the amount of approximately \$700 and \$1,100 during the three and six months periods ended June 30, 2006, respectively.

d. In July 2006, the FASB issued FASB Interpretation No. 48 "Accounting for Uncertainty in Income Taxes an Interpretation of FASB Statement No. 109" ("FIN 48"). FIN 48 clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. FIN 48 utilizes a two-step approach for evaluating tax positions. Recognition (step one) occurs when an enterprise concludes that a tax position, based solely on its technical merits, is more-likely-than-not to be sustained upon examination. Measurement (step two) is only addressed if step one has been satisfied (i.e., the position is more-likely-than-not to be sustained). Under step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis that is more-likely-than-not to be realized upon ultimate settlement.

FIN 48 applies to all tax positions related to income taxes subject to the Financial Accounting Standard Board Statement No. 109, "Accounting for income taxes" ("FAS 109"). This includes tax positions considered to be "routine" as well as those with a high degree of uncertainty.

FIN 48 has expanded disclosure requirements, which include a tabular roll forward of the beginning and ending aggregate unrecognized tax benefits as well as specific detail related to tax uncertainties for which it is reasonably possible the amount of unrecognized tax benefit will significantly increase or decrease within twelve months. These disclosures are required at each annual reporting period unless a significant change occurs in an interim period.

FIN 48 is effective for fiscal years beginning after December 15, 2006. The cumulative effect of applying FIN 48 will be reported as an adjustment to the opening balance of retained earnings.

The Company is currently evaluating the effect of the adoption of FIN 48 on its financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 3:- MAJOR TRANSACTIONS

a. Partner Communications Company Ltd. ("Partner")

On March 21, 2006, Elron completed the acquisition of approximately 823,000 shares of Partner from one of the other Israeli founding shareholders of Partner for approximately \$5,300, reflecting approximately 15% discount from the market price at the date of the agreement. Upon completion of the acquisition, Elron holds approximately 2.6% of Partner.

Almost all of Partner shares held by the Company are subject to certain transfer restrictions under Partner's Israeli Communications license. The shares are accounted for as available-for-sale securities.

b. **Nulens**

As described in Note 8 (c) to the Company's annual financial statements, on April 21, 2005, Elron completed an investment of approximately \$2,900 in Nulens Ltd. ("Nulens"), in consideration for 763,584 Series A preferred shares, as part of an aggregate investment of approximately \$3,400. Elron's investment was in two installments, the first of approximately \$1,700 was invested immediately for approximately 17% of Nulens on a fully diluted and on an as converted basis and an additional amount of approximately \$1,100 was invested on March 9, 2006. Simultaneously with the \$1,100 investment, Elron invested an additional amount of \$1,500in 241,158 Series B preferred shares. The investment in preferred B shares was part of a new round of investment in the aggregate amount of approximately \$6,000. The new round was led by Warburg Pincus, a leading global private equity fund. Following the above investments, Elron holds 25% of Nulens, on a fully diluted and on an as converted basis. Nulens is an Israeli medical devices company operating in the field of intra-ocular lenses mainly for cataract and presbyopia procedures.

Since the investments in preferred A and B shares are not considered to be investments that are in-substance-common stock, the investment in Nulens is accounted for under the cost method.

c. Safend

On January 2, 2006, Elron completed an investment of approximately \$3,700 in Safend Ltd. ("Safend"), in consideration for 1,942,261 Series B preferred shares, as part of an aggregate investment of approximately \$7,400. Following Elron's investment, Elron holds approximately 22% of Safend on a fully diluted and on an as converted basis. Safend is an Israeli company which develops comprehensive desktops and laptops endpoint security solutions.

Since the investment in preferred B shares is not considered to be an investment that is insubstance-common stock, the investment in Safend is accounted for under the cost method.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 3:- MAJOR TRANSACTIONS (Cont.)

d. Mediagate

In February 2006, Mediagate's bank loan in the amount of approximately \$2,800 was settled in consideration for \$100. As a result, according to the provisions of FAS 140 "Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities" Elron recorded in the first quarter of 2006 a gain of approximately \$2,700 which is included in other income in the statements of operations.

e <u>AMT</u>

On June 8, 2006, Elron completed an investment of \$5,000 in convertible A1 notes of Advanced Metal Technology Ltd. (AMT), as part of a financing round of \$14,000 led by Shamrock Israel Growth Fund, an Israeli private equity fund. The investment in AMT was in two installments, the first of \$2,500 was invested immediately, and the additional \$2,500 investment is subject to certain conditions. In addition, Elron and other shareholders of AMT converted previously granted loans in the amount of \$1,000 into convertible A1 notes of AMT, of which Elron's share is \$500. Following the above investment, Elron's holdings in AMT decreased from approximately 42% to 34% on an as converted basis. The decrease in holdings had no effect on the results of operations.

f. **GIVEN**

Subsequent to the balance sheet date, Elron has purchased, in a series of open market transactions, approximately 540,000 ordinary shares of Given Imaging Ltd. ("Given"), for an aggregate purchase consideration of approximately \$10,000. As a result of the transactions, Elron's direct and indirect ownership interest in Given (through its direct holdings and its holdings in its subsidiary, RDC-Rafael Development Corporation Ltd.) increased from approximately 19.3% to approximately 21.2% of Given outstanding ordinary shares. In parallel transactions, DIC purchased the same number of shares of Given for the same aggregate consideration, increasing its holding in Given from approximately 12.4% to approximately 14.3% of Given's outstanding ordinary shares.

g. ONCURA

In light of Oncura's results, the Company recorded in the second quarter of 2006 an impairment loss on the investment in Oncura in the amount of \$6.1 (\$2.5 net of minority interest), due to an other than temporary decline in value of such investment. The impairment loss was presented in the statement of operations in the line item "equity in losses of affiliated companies".

NOTE 4:- CONTINGENT LIABILITIES

There were no material changes in the status of the Company's contingent liabilities as described in the Company's annual financial statements, the details of which are as follows:

1. During September 1999, the Company received copies of two claims and a request to approve such claims as a class action on behalf of public shareholders of Elscint (formerly an affiliated company) against the Company and others. The allegation raised by the claimants related to the decision regarding the sale of Elscint's substantial assets. The claim has been stayed pursuant to an arrangement reached by the parties pending the outcome of the appeal in the claim described in paragraph 2 below. The arrangement

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 4:- CONTINGENT LIABILITIES (Cont.)

provides that if the appeal as described in paragraph 2 below is accepted, then the proceedings to recognize the lawsuit as a class action will proceed. Otherwise, the application to recognize the claim as a class action suit will be dismissed.

2. On November 2, 1999, the Company received a copy of a claim, and a request to approve such a claim, as a class action on behalf of some institutional investors and others and those who held shares in Elscint on September 6, 1999. The allegations raised against the

Company and certain of its officers including former officers, among others, relate to the period prior to the sale of the Company's holdings in Elbit Medical Imaging ("EMI") (the parent company of Elscint and formerly an affiliated company). The claimants seek a court order pursuant to which EMI would be compelled to execute the alleged buy-out of Elscint's share at \$14 per share or other remedies. On August 16, 2000, the Haifa District court dismissed the application to recognize the claim as a class action. Some of the claimants applied for and have been granted permission to appeal to the Supreme Court in Israel, which appeal is currently pending.

In addition, in February 2001, the claimants submitted a revised claim similar to the previous one but not as a class action. It has not been determined when the defendants are required to file their statements of defense to the claim. The claimants and the defendants are currently involved in various proceedings, mostly regarding the disagreement concerning the court fees.

The Company denies all the allegations set forth in the above claims, and based on legal advice received, management is of the opinion that the Company has good defense arguments which, if accepted, will cause dismissal of the above allegations.

NOTE 5:- RECONCILIATION TO ISRAELI GAAP

The consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP. Had the consolidated financial statements been prepared in accordance with Israeli GAAP, the effects on the financial statements would have been as follows:

a. Effect on the statement of operations:

	Six months ended June 30, 2006										
	<u>A</u>	s reported		ljustments Jnaudited	As	as per Israeli GAAP					
Net loss Basic net loss per share Diluted net loss per share	\$	(9,938) (0.34) (0.35)	\$	(8,027) (0.27) (0.27)	\$	(17,965) (0.61) (0.62)					
		Six months ended June 30, 2005									
	_ A	As reported		ljustments Jnaudited	As per Israel GAAP						
Net income Basic net loss per share Diluted net loss per share	\$	42,087 1.43 1.42	\$	18,217 0.62 0.62	\$	60,304 2.05 2.04					

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 5:- RECONCILIATION TO ISRAELI GAAP (Cont.)

a. Effect on the statement of operations: (Cont.)

	Three months ended June 30, 2006									
	As	s reported	Adjustments Unaudited			per Israeli GAAP				
Net loss Basic net loss per share Diluted net loss per share	\$	(6,425) (0.22) (0.22)	\$	(3,345) (0.11) (0.11)	\$	(9,770) (0.33) (0.33)				
		Three	montl	ns ended Jun						
	A	s reported		ljustments_ Unaudited	As	per Israeli GAAP				
Net income Basic net loss per share Diluted net loss per share	\$	47,200 1.60 1.60	\$	20,789 0.71 0.71	\$	67,989 2.31 2.31				
		Yea	r ende	d December						
	_A	s reported	Ac	ljustments Audited	As	per Israeli GAAP				
Net income Basic net income per share Diluted net income per share	\$	47,335 1.61 1.60	\$	7,147 0.24 0.24	\$	54,482 1.85 1.84				
Effect on the balance sheet:			_							
	A	s reported	Ac	ljustments Unaudited	As	per Israeli GAAP				
Total assets Total liabilities including minority	\$	335,811	\$	(77,368)	\$	258,443				
interest Total equity		44,389 291,422		(16,573) (60,795)		27,816 230,627				
	December 31, 2005									
	A	s reported		ljustments ıdited	As	per Israeli GAAP				
Total assets	\$	353,773	\$	(75,361)	\$	278,412				
Total liabilities including minority interest Total equity		51,657 302,116		(21,145) (54,216)		30,512 247,900				

c. Material adjustments:

b.

The abovementioned adjustments result primarily from the differences between U.S. GAAP and Israeli GAAP detailed in Note 26 to the Company's annual financial statements for 2005.

ANNEX TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

Details relating to major investments as of June 30, 2006:

	% of	Carrying value of the investment as of	tra investm	of the publicly ided ents as of:
	ownership interest ⁽¹⁾	June 30, 2006 ⁽²⁾	June 30, 2006	August 9, 2006
Consolidated Companies:				
Galil Medical Ltd. (3)	40%	1,771	-	-
3DV Systems Ltd. (3)	62%	(225)	-	-
Starling (3)	50%	476	-	-
SELA (3)	39%	916	-	-
Enure (formerly: Gaia)	57%	2,109	-	_
Mendingo (3)	50%	5	-	-
Affiliated Companies (equity):				
Given Imaging Ltd. (Nasdaq: GIVN) (3) (5)	19%	61,611	82,930	107,990
NetVision Ltd. (TASE: NTSN)	39%	8,118	39,476	39,554
ChipX	29%	3,789	-	-
CellAct Ltd.	45%	468	-	-
Oncura ⁽⁴⁾ AMT	10% 34%	6,016	-	-
Wavion, Inc.	34% 38%	3,151 1,095	-	-
Pulsicom Israel Technologies Ltd.	18%	1,093	_	
Notal Vision, Inc.	23%	-	-	-
Available for sale:				
Partner (Nasdaq: PTNR)	3%	29,569	32,140	35,741
EVS (Nasdaq: EVSNF.OB)	9%	1,215	1,509	1,509
Partnership:				
Gemini Israel Fund L.P.	5%	33	-	-
InnoMed Ventures L.P.	14%	3,347	-	-
Cost:				
Jordan Valley	28%	8,137	-	-
Impliant Tale 144	22%	8,340	-	-
Teledata Ltd.	21%	16,000	-	-
Nulens Ltd.	29% 22%	4,360	-	-
Brainsgate Ltd. Safend Ltd.	22% 26%	6,947 3,700	-	-
Salcha Lia.	2070	3,700	-	-

⁽¹⁾ On the basis of the outstanding share capital.

⁽²⁾ Includes loans and convertible notes.

⁽³⁾ Represents the carrying value and the ownership interest of the investment in Elron's books and Elron's share in the carrying value and ownership interest of the investment in RDC's books.

Represents Elron's share in the carrying value and the ownership interest of the investment in Galil's books.

During August 2006 Elron purchased 539,721 ordinary shares of Given in consideration for approximately \$10,000 and as a result Elron's % of ownership interest was increased from 19.3% to 21.2%.